THE J. DAVID GLADSTONE INSTITUTES Patent applications |
Patent application number | Title | Published |
20150157584 | INHIBITORS OF HIPPO-YAP SIGNALING PATHWAY - This invention provides methods of preventing, reducing, delaying or inhibiting the proliferation, growth, migration and/or metastasis of cancer by administering an effective amount of an inhibitor of the Hippo-YAP signaling pathway. | 06-11-2015 |
20150037290 | Methods of Modulating Smooth Muscle Cell Proliferation and Differentiation - The present disclosure provides methods of inducing smooth muscle cell differentiation. The present disclosure provides genetically modified cells comprising exogenous miR-143 and/or miR-145 nucleic acids; and artificial tissues comprising the genetically modified cells. The present disclosure provides methods and compositions for reducing pathological angiogenesis. The present disclosure provides methods of inducing therapeutic angiogenesis. The present disclosure provides methods, compositions, and devices for inhibiting vascular smooth muscle cell proliferation. | 02-05-2015 |
20140301991 | Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes. | 10-09-2014 |
20140235526 | Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes. | 08-21-2014 |
20140234302 | Methods and Compositions for Reducing Amyloid Beta Levels - The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity. | 08-21-2014 |
20140065206 | Agents that Reduce Neuronal Overexcitation - The present invention provides methods of identifying candidate agents for treating excitotoxicity-related disorders. The present invention further provides methods for treating excitotoxicity-related disorders. | 03-06-2014 |
20140030295 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response - The present disclosure provides a method of increasing an immune response in an individual, the method involving administering to an individual in need thereof an inhibitor of SIRT1. The present disclosure provides a method of reducing an immune response, e.g., to treat chronic immune hyperactivity, the method generally involving administering to an individual in need thereof an activator of SIRT1. The present disclosure provides a method of modulating activation and differentiation of CD4 | 01-30-2014 |
20130323279 | Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof - The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide. | 12-05-2013 |
20130216503 | Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes. | 08-22-2013 |
20130095113 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS - The present disclosure provides methods for treating neurological disorders, generally involving modulating protein kinase D1 (PKD1) activity levels in a neuron or glial cell in an individual in need thereof. The present disclosure provides antibodies specific for PKD1. The present disclosure provides a genetically modified non-human mammal deficient in PKD1 activity. | 04-18-2013 |
20110135613 | METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS - The present disclosure provides a method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele. The method generally involves reducing tau levels in the interneuron. | 06-09-2011 |
20110135611 | METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS - The present disclosure provides methods of reducing apoE4 fragment-mediated toxicity of interneurons, e.g, GABAergic interneurons. The present disclosure provides methods of treating apoE4-mediated neurological disorders in an apoE4-positive individual. | 06-09-2011 |
20110046042 | Long Interspersed Nuclear Element Polypeptide Compositions and Methods of Use Thereof - The present invention provides LINE polypeptides; and compositions, including immunogenic compositions, comprising a subject LINE polypeptide. The present invention provides a recombinant nucleic acid comprising a nucleotide sequence encoding a subject LINE polypeptide. A subject composition is useful for stimulating a T-cell immune response to a LINE peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers that are associated with tissues in which LINE polypeptides are aberrantly expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a LINE polypeptide. | 02-24-2011 |
20100021912 | Methods of Modulating Lipid Concentrations in Eukaryotic Cells - The present invention is based on the discovery of a set of genes that are involved in lipid-droplet formation and regulation. Accordingly, the present invention provides methods of increasing or decreasing lipid concentrations in eukaryotic cells by decreasing or increasing expression of one of these genes. Increased lipid concentrations may be useful, for example, in the generation of biofuels. Decreased lipid concentration may be useful in the treatment of diseases characterized by excessive lipid storage. In addition, the invention provides methods of identifying markers of diseases characterized by excessive lipid storage. | 01-28-2010 |
20090061015 | Regulation of Protein Activity By Reversible Acetylation - This invention discloses the first cellular acetylated substrate protein of SIRT3, Acetyl-CoA synthetase 2 (AceCS2), which is a mitochondrial matrix protein. AceCS2 is reversibly acetylated at lysine 642 (Lys642) in the active site of the enzyme. The mitochondrial sirtuin SIRT3 interacts with AceCS2 and deacetylates Lys642 both in vitro and in vivo. Deacetylation of AceCS2 by SIRT3 activates the acetyl-CoA synthetase activity of AceCS2. Thus, a mammalian sirtuin directly controls the activity of a metabolic enzyme via reversible lysine acetylation. Modulators of the acetylation status or the activity of AceCS2 are useful for the treatment of pathological conditions, such as type II diabetes, hypercholesterolemia, hyperlipidemia, and obesity. | 03-05-2009 |
20080233581 | HISTONE DEACETYLASE AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that encode histone deacetylase, as well as recombinant vectors and host cells that include the subject nucleic acid molecules. Also provided are histone deacetylase polypeptide compositions. The histone deacteylase nucleic acid molecules are useful in a variety of diagnostic and therapeutic applications, which are also provided. | 09-25-2008 |
20080200566 | Dephosphorylation of HDAC7 By Myosin Phosphatase - The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase. | 08-21-2008 |